|
|
||||
|
|
||||
|
||||
Tumor Biology |
Department of Neurosurgery, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298, USA (T.E.V., W.C.B., H.L.F); Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, School of Pharmacy and Biomedical Sciences, St. Michael's Building, White Swan Road, Portsmouth, Hampshire PO1 2DT, England (H.K.R., G.J.P.); Cellular and Molecular Neuro-Oncology Research Group (H.K.R., G.J.P.)
2 Address correspondence to Helen L. Fillmore, Department of Neurosurgery, Virginia Commonwealth University, Medical College of Virginia Campus, West Hospital 8th Floor, 1200 East Broad Street, Richmond, VA 23298, USA (hfillmor{at}hsc.vcu.edu).
Abstract
Increased expression of membrane-type matrix metalloproteinases (MT-MMPs) has previously been reported to correlate with increasing grade of malignancy in gliomas, a relationship shared with alterations in epidermal growth factor receptor (EGFR) signaling. To investigate the possibility of a causative role for EGFR signaling in increasing MT-MMP expression and subsequent peritumoral proteolysis, we characterized glioma cell lines for expression of MT1-MMP, MT2-MMP, MT3-MMP, and MT5-MMP by Western blotting and by quantitative real-time polymerase chain reaction analysis, and for MMP-2 activity following epidermal growth factor (EGF) stimulation. EGF stimulation of glioma cell lines resulted in a 2- to 4-fold increase in MT1-MMP mRNA levels. Although there were slight differences in MT2-, MT3-, and MT5-MMP mRNA expression following EGF stimulation, none of these demonstrated an increase similar to that of MT1-MMP expression. Treatment of high-grade glioma cell lines U251MG and IPSB-18 with EGF for 24 h resulted in a several-fold increase in MT1-MMP protein (2.5- and 5.1-fold, respectively) and in cyclin D1 (2.9-fold), as compared to untreated controls. No significant increase was detected in other MT-MMPs at the protein level. Although there was no detectable increase in proMMP-2 protein, there was an increase in MMP-2 activity. Furthermore, the MT1-MMP induction by EGF was prevented by pretreatment with the EGFR-specific tyrphostin inhibitor AG1478. Similarly, treatment with the phosphatidylinositol 3-kinase inhibitor LY294002 prevented the induction of MT1-MMP protein by EGF stimulation. These compounds additionally inhibited EGF-stimulated invasion in Matrigel Transwell assays. Our results indicate that one mechanism of EGFR-mediated invasiveness in gliomas may involve the induction of MT1-MMP.
This article has been cited by other articles:
![]() |
H.-D. Kim, T. W. Guo, A. P. Wu, A. Wells, F. B. Gertler, and D. A. Lauffenburger Epidermal Growth Factor-induced Enhancement of Glioblastoma Cell Migration in 3D Arises from an Intrinsic Increase in Speed But an Extrinsic Matrix- and Proteolysis-dependent Increase in Persistence Mol. Biol. Cell, October 1, 2008; 19(10): 4249 - 4259. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ouyang, S. Lu, X.-Y. Li, J. Xu, J. Seong, B. N. G. Giepmans, J. Y.-J. Shyy, S. J. Weiss, and Y. Wang Visualization of Polarized Membrane Type 1 Matrix Metalloproteinase Activity in Live Cells by Fluorescence Resonance Energy Transfer Imaging J. Biol. Chem., June 20, 2008; 283(25): 17740 - 17748. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Langlois, C. Nyalendo, G. Di Tomasso, L. Labrecque, C. Roghi, G. Murphy, D. Gingras, and R. Beliveau Membrane-Type 1 Matrix Metalloproteinase Stimulates Cell Migration through Epidermal Growth Factor Receptor Transactivation Mol. Cancer Res., June 1, 2007; 5(6): 569 - 583. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-C. Currie, S. Fortier, A. Sina, J. Galipeau, J. Cao, and B. Annabi MT1-MMP Down-regulates the Glucose 6-Phosphate Transporter Expression in Marrow Stromal Cells: A MOLECULAR LINK BETWEEN PRO-MMP-2 ACTIVATION, CHEMOTAXIS, AND CELL SURVIVAL J. Biol. Chem., March 16, 2007; 282(11): 8142 - 8149. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhang, S. Sarkar, and V.W. Yong The chemokine stromal cell derived factor-1 (CXCL12) promotes glioma invasiveness through MT2-matrix metalloproteinase Carcinogenesis, December 1, 2005; 26(12): 2069 - 2077. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Kaur, F. W. Khwaja, E. A. Severson, S. L. Matheny, D. J. Brat, and E. G. Van Meir Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis Neuro-oncol, April 1, 2005; 7(2): 134 - 153. [Abstract] [PDF] |
||||
|
|